Market Research Logo

PharmaFocus: Tauopathies - Global Market Analysis

PharmaFocus: Tauopathies - Global Market Analysis

Summary

Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no treatments approved in this therapy area and five tauopathies are attracting increasing attention from pharmaceutical companies in particular. These are: progressive Supranuclear palsy (PSP), CorticoBasal Degeneration (CBD), frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17), Pick’s disease (clinically referred to as bvFTD), and chronic traumatic encephalopathy (CTE). In these indications, symptoms often present as behavioral (e.g. disinhibition, apathy), cognitive (e.g. memory loss), language (e.g. slurring of speech), or motor (e.g. falls, tremor) deficits.

According to Akiko Fukui, Healthcare Analyst, there are currently no approved therapies to treat tauopathy patients, and as such, the first-to-market drug will secure a high patient share, boosting sales and establishing a strong company presence in the tauopathies space. In turn, the market will be made more attractive for other manufacturers, as strong sales performance of the first product will reduce financial risk. Moreover, the possibility of expanding sales from the tauopathies market into the much larger Alzheimer’s disease space is another strong incentive for drug manufacturers, as successful entry into these markets would provide huge revenue.

The report “PharmaFocus: Tauopathies - Global Market Analysis” states that once the first drug in the tauopathies market is approved, it could incentivize R&D from other pharma companies, setting an example for an effective therapeutic approach and regulatory approval process. Additionally, the approval of a drug in one tauopathy indication is likely to prompt its off-label use in other indications, driving sales further.

In particular, the report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global tauopathy therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global tauopathy therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Scope
  • Overview of tauopathies including, etiology, pathophysiology, symptoms, diagnosis, and clinical trial challenges.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the tauopathy therapeutics market.
  • Pipeline analysis: focus on four late-stage pipeline tauopathy drugs, discussing emerging trends as well as an overview of earlier phase and preclinical drugs.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global tauopathy therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global tauopathy therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.


  • Executive Summary
  • Introduction
    • Catalyst
    • Related Reports
  • Disease Overview
    • Etiology and Pathophysiology
      • Table Main Distinctions of the FiveTauopathies
      • Table Figure 1: Key Atrophic Brain Regions Involved in Tauopathies
      • Etiology
        • Table Genetic Traits in Tauopathies
        • Table Figure 2: Location of MAPT Gene Within Chromosome 17
      • Pathophysiology
        • Table Isoform Expressions in Tauopathies
        • Table Figure 3: Tau 3R and 4R Isoforms Coded by the MAPT Gene
        • Table Figure 4: Mechanisms Involved in Tau Dissociation from the MTs
    • Classification
      • Clinical Classification
        • Table Figure 5: Classification of Tauopathies According to Symptoms
      • Pathological Classification
        • Table Figure 6: Classification of Primary and Secondary Tauopathies
        • Table Cellular Tau Pathology in Different Tauopathies
      • Classification According to 4R:3R Ratio
    • Symptoms
      • Table Characteristic Symptoms of Tauopathies
    • Diagnosis
      • Patient Journey
      • Clinical Assessments
        • Table Classification and Criteria of FTD According to DSM-V and ICD-10-CM
    • Biomarkers
      • Diagnostic Markers
        • Table Diagnostic Markers for Tauopathies
      • Biomarkers in Drug Development
      • Promising Biomarkers
    • Prognosis
    • Quality of Life
  • Current Treatment Paradigm
    • Overview
    • Treatment Paradigm
      • Table Treatments for Tauopathies, 2016
    • Anti-Parkinson's Drugs
      • Amantadine
      • Dopamine Receptor Agonists
      • Levodopa
    • Antidepressant Drugs
      • Selective Serotonin Reuptake Inhibitors
      • Trazodone
      • Tricyclic Antidepressants
    • Anti-Alzheimer's Drugs
      • Acetylcholinesterase Inhibitors
      • Memantine
    • Other Therapeutic Agents
      • Antiepileptics
      • Antipsychotics
      • Onabotulinum Toxin A
    • Non-pharmacological Therapies
  • Unmet Needs and Opportunities
    • Overview
      • Table Unmet Need and Opportunity in Tauopathies
    • Development of Disease-Modifying Therapies
      • Unmet Need
      • Gap Analysis
      • Opportunity
    • Development of More Effective Symptomatic Treatments
      • Unmet Need
      • Gap Analysis
      • Opportunity
    • Improved Biomarkers to Evaluate Drug Efficacy
      • Unmet Need
      • Gap Analysis
      • Opportunity
    • Biomarkers for Clinical Diagnosis
      • Unmet Need
      • Gap Analysis
      • Opportunity
    • Greater Support for Patients
      • Unmet Need
      • Gap Analysis
      • Opportunity
  • Pipeline Assessment
    • Overview
    • Clinical Trial Mapping
      • Clinical Trials by Class of Therapy
        • Table Figure 7: Tauopathies Therapeutics - Clinical Trials in the 7MM, 2016
    • Drugs in Late-Stage Clinical Development
      • Table Drugs in Clinical Development for Tauopathies, 2016
      • Table Figure 8: Tauopathies Phase II/Phase III Pipeline, 2016
      • Table Comparison of Drugs in Development for Tauopathies, 2016
      • AVP-786
        • Table Product Profile - AVP-786
        • Table AEs at > 3% Incidence in PBA Trials of Nuedexta
        • Table SWOT Analysis - AVP-786, 2016
      • Masitinib
        • Table Product Profile - Masitinib
        • Table SWOT Analysis - Masitinib, 2016
      • TRx-237
        • Table Product Profile - TRx-237
        • Table SWOT Analysis - TRx-237, 2016
      • Zolpidem Tartrate
        • Table Product Profile - Zolpidem
        • Table AEs at > 1% Incidence in Insomnia Trials of Zolpidem Lasting up to 10 Nights
        • Table AEs at > 1% Incidence in Insomnia Trials of Zolpidem Lasting up to 35 Nights
        • Table SWOT Analysis - Zolpidem, 2016
    • Drugs in Early-Stage Clinical Development
      • Table Drugs in Early-Stage Clinical Development for Tauopathies, 2016
      • ABBV-8E12
      • AZP-2006
      • BMS-986168
      • DC-TAB
      • MK-8719
      • TPI-287
    • Drugs in Preclinical/Discovery Development
      • Table Drugs in Preclinical Development for Tauopathies, 2016
      • ASN-561
      • ANAVEX-3-71
      • Cannabidiol
      • DP-C016
      • EU-C-001
      • GTC-6000
      • N-acetylcysteine Amide
      • NI-205/NI-308
      • PBT-434
      • Anti-TauC3
  • R&D Strategies and Clinical Trial Design
    • Overview
      • Trends in Corporate Strategies
      • Novel Research Strategies
        • Table Comparison of Novel Research Strategies for Tauopathies, 2016
        • Table Figure 9: Novel Strategies for Tauopathy Treatment, 2016
      • Clinical Trial Design
        • Table Clinical Trial Design of Key Pipeline Drugs for Tauopathies, 2016
        • Table Recently failed major trials in tauopathies
        • Table Common Primary and Secondary Outcome Measures in Tauopathies Clinical Trials
  • Market Drivers and Barriers
    • Overview
      • Table Tauopathies - Market Drivers and Barriers
    • Driver: First-to-Market Drug Will Boost Sales and Encourage Pharma Companies to Focus R&D Efforts in This Market
    • Driver: Approval of Drug in One Tauopathy Indication is Likely to Prompt its Off-Label Use in Others
    • Driver: Any Tauopathy-Approved Drug Is Likely to Enter the Lucrative Alzheimer's DiseaseMarket
    • Driver: Regulatory Agencies Provide Orphan Designations to Drug Candidates
    • Driver: Therapies Are Likely to Have Premium Pricing
    • Barrier: No Biomarker to Measure Clinical Efficacy
    • Barrier: Low Accuracy in Diagnostic Methods
    • Barrier: Tauopathies Market Is a High-Risk Indication
    • Barrier: Low Public Awareness of These Disorders
  • Appendix
    • Bibliography
    • Abbreviations
    • Methodology
    • Primary Research - KOLs Interviewed for This Report
    • About the Authors
      • Analyst
      • Therapy Area Director
      • Global Director of Therapy Analysis and Epidemiology
    • About GlobalData
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report